Evidence map›Paper›PMID 34193287›Full record

ArticleEuropean journal of medical research2021

Determination of parasitic burden in the brain tissue of infected mice in acute toxoplasmosis after treatment by fluconazole combined with sulfadiazine and pyrimethamine.

Sekandarpour Sina, Jafari Modrek Mohammad, Shafiei Reza, Mohammadiha Anita, Etemadi Soudabeh, Mirahmadi Hadi

Open access · goldAbstract read
In one paragraph

Article in European journal of medical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Sekandarpour SinaInfectious Disease and Tropical Medicine Research Center, Resistance Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran.
Jafari Modrek MohammadInfectious Disease and Tropical Medicine Research Center, Resistance Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran.
Shafiei RezaVector-Borne Diseases Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran.
Mohammadiha AnitaDepartment of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Etemadi SoudabehInfectious Disease and Tropical Medicine Research Center, Resistance Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran.
Mirahmadi HadiInfectious Disease and Tropical Medicine Research Center, Resistance Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran. hmirahmadi59@gmail.com.
Zahedan University of Medical Sciences · IRNorth Khorasan University of Medical Sciences · IRTarbiat Modares University · IR

Funding

Zahedan University of Medical Sciences 1192
6 · The paper itself

Abstract

BACKGROUND/

aimsOne of the opportunistic pathogens which cause serious problems in the human immune system is Toxoplasma gondii, with toxoplasma encephalitis (TE) seen in patients affected by it. The treatment of these patients is limited, and if not treated on time, death will be possible.

methodsIn this study, the effects of the treatment with different doses of fluconazole (FLZ) in combination with the current treatment of acute toxoplasmosis on reducing the mortality rate and the parasitic load in the murine model in vivo were studied. The mice were treated with different doses of fluconazole alone, sulfadiazine, and pyrimethamine plus fluconazole. A day after the end of the treatment and 1 day before death, the mice's brains were collected, and after DNA extraction and molecular tests, the parasite burden was detected.

resultsThis study showed that a 10-day treatment with 20 mg/kg of fluconazole combined with sulfadiazine and pyrimethamine 1.40 mg/kg per day affected acute toxoplasmosis and reduced the parasitic load significantly in brain tissues and also increased the survival rate of all mice in this group until the last day of the study, in contrast to other treatment groups. These results also indicate the positive effects of combined therapy on Toxoplasma gondii and the prevention of relapse.

conclusionsReducing the parasitic burden and increasing the survival rate were more effective against acute toxoplasmosis in the combined treatment of different doses of fluconazole with current treatments than current treatments without fluconazole. In other words, combination therapy with fluconazole plus pyrimethamine reduced the parasitic burden in the brain significantly, so it could be a replacement therapy in patients with intolerance sulfadiazine.

Indexed as

14-alpha Demethylase InhibitorsAcute DiseaseAnimalsAntiprotozoal AgentsBrainDisease Models, AnimalDrug Therapy, CombinationFemaleFluconazoleMiceMice, Inbred BALB CPyrimethamineSulfadiazineToxoplasmaToxoplasmosis, Cerebral14-alpha Demethylase InhibitorsAntiprotozoal AgentsFluconazolePyrimethamineSulfadiazineDrugParasitic burdensReal-time PCRToxoplasma gondii

Identifiers

PMID34193287
PMCPMC8243906
OpenAlexW3175620382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.